EQUULEUS: what clinicians are saying
daratumumab plus carfilzomib plus dexamethasone; daratumumab plus pomalidomide plus dexamethasone; daratumumab plus carfilzomib plus lenalidomide plus dexamethasone in multiple myeloma · NCT01998971 ↗ · Phase 1 · Janssen Research & Development, LLC
A physician supports weekly D-Kd in EQUULEUS while relaying a cross-study comparison suggesting similar benefit and safety; this does not establish schedule equivalence. A medical oncologist considers prior treatment and refractoriness relevant to D-Pd/Isa-Pd selection but offers no sequencing rule. Direct commentary on the trial is brief; broader discussion of frontline anti-CD38 combinations and maintenance provides context rather than evidence of this trial’s outcomes.
Created with AI · how we check it
- edition 1
- commentary checked Nov 18, 2026
- 244 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
15 findings, and what sits behind each
01. Weekly KdD70: why a clinician welcomes the dosing option
1 of the report's 7 cited clinicians · 9 statements from 1 speaker in 4 sources · 6 passages
Limitations recorded: 3.
Draws on: The comparison, Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT), Secondary endpoints, Safety and tolerability, Design and conduct.
02. Anti-CD38–pomalidomide triplets: a clinician weighs prior lines and refractory status
1 of the report's 7 cited clinicians · 3 statements from 1 speaker in 2 sources · 4 passages
Limitations recorded: 2.
Draws on: Population and setting, The comparison.
03. D-Kd: a clinician welcomes approval but hopes for future regional access
1 of the report's 7 cited clinicians · 1 statement from 1 speaker in 1 source · 2 passages
Limitations recorded: 1.
Draws on: Population and setting.
04. DREAMM-7: how a speaker weighs potential benefit against vision risks
No named clinician · accounts and unnamed speakers · 7 statements from 1 speaker in 1 source, a podcast or video · 5 passages
Limitations recorded: 3.
Beyond the trial population
05. Single-drug maintenance: a clinician favors daratumumab over lenalidomide
1 of the report's 7 cited clinicians · 3 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 2.
06. CD38 maintenance: how a clinician weighs CD38-naïve data against post-quadruplet gaps
1 of the report's 7 cited clinicians · 16 statements from 1 speaker in 2 sources, all podcasts or videos · 10 passages
Limitations recorded: 4.
07. MRD-informed treatment reduction: where clinicians split on whether and when to stop
4 of the report's 7 cited clinicians · 26 statements from 4 speakers in 4 sources, all podcasts or videos · 16 passages
Limitations recorded: 5.
08. Transplant deferral: how clinicians weigh MRD, disease risk and fitness
2 of the report's 7 cited clinicians · 13 statements from 2 speakers in 2 sources, all podcasts or videos · 8 passages
Limitations recorded: 4.
09. Frontline quadruplets: most clinicians favor use, but one flags uneven uptake
3 of the report's 7 cited clinicians · 27 statements from 3 speakers in 4 sources, all podcasts or videos · 18 passages
Limitations recorded: 3.
10. Quadruplets in older age: why most clinicians favor selected use with dose adjustments
3 of the report's 7 cited clinicians · 22 statements from 3 speakers in 3 sources, all podcasts or videos · 12 passages
Limitations recorded: 4.
11. Early dexamethasone stopping: a clinician sees a future template, not a universal rule
2 of the report's 7 cited clinicians · 9 statements from 3 speakers in 2 sources, all podcasts or videos · 6 passages
Limitations recorded: 3.
12. Carfilzomib: how a clinician weighs neuropathy, disease risk, access and cardiac risk
2 of the report's 7 cited clinicians · 18 statements from 2 speakers in 2 sources, all podcasts or videos · 15 passages
Limitations recorded: 4.
13. Lenalidomide: a clinician favors early use but awaits stable renal function
1 of the report's 7 cited clinicians · 6 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 2.
14. CD38 antibodies: how clinicians weigh dosing and delivery experience
2 of the report's 7 cited clinicians · 14 statements from 2 speakers in 3 sources, all podcasts or videos · 9 passages
Limitations recorded: 4.
15. CD38 care: a clinician stresses prevention; one plans for long-term therapy
2 of the report's 7 cited clinicians · 16 statements from 2 speakers in 2 sources, all podcasts or videos · 9 passages
Limitations recorded: 5.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 15
1 of the report's 7 cited clinicians
Weekly KdD70: why a clinician welcomes the dosing option
9 statements from 1 speaker in 4 sources
The one named speaker in this finding holds this view, a confirmed clinician
- 9
- statements
- 6
- passages
- 4
- sources
- 1
- speaker
What the statements areViews 2Questions and uncertainty 0Clinical experience 0Comparisons 2Restated results and context 5Statement-to-passage links (a passage can back several statements)Supporting a statement 9Giving context 1Recorded with the findingLimitations: 3
2 posts and articles · 2 publications
Draws on: The comparison, Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT), Secondary endpoints, Safety and tolerability, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
11 of the 15 findings and 162 of the 244 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MRD, measurable residual disease; NPI, National Provider Identifier, the US registry number for clinicians.
The full EQUULEUS report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 34commentary sources screened
- 15sources cited by verified statements
- 9named in screened sources
- 9speakers cited in the report
- 7cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 4 physician, specialty not confirmed
- 3 physician, Medical oncology
Also in the sources: 4 organizational or shared accounts, not counted as people.
- 244verified statements, each linked to its source
- 93of them from speakers with a confirmed clinical role
- 15findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 15 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 244 | Paid |
| Who said each statement: the cited speakers | 9 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 7 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 20 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
19 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) | 2 | 2 |
| Primary endpoint: Number of participants affected by dose-limiting toxicitiesno commentary found | 0 | 0 |
| Secondary endpoints | 2 | 2 |
| Population and setting | 3 | 2 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 4 | 3 |
| Safety and tolerability | 2 | 2 |
| Design and conduct | 2 | 2 |
| Access-dependent regimen use | 6 | 3 |
| DREAMM-7 as an alternative-treatment discussion involving D-Vd | 7 | 1 |
| Maintenance component selection after contemporary frontline therapy | 8 | 3 |
| PERSEUS and AURIGA maintenance interpretation and prior CD38 exposure | 17 | 2 |
| MRD-informed decisions, treatment duration and treatment-free intervals | 26 | 4 |
| Transplantation after quadruplet induction and selective deferral | 13 | 2 |
| Contemporary frontline quadruplet rationale and implementation | 24 | 4 |
| Fitness, cytogenetic work-up and attenuated treatment in older patients | 22 | 3 |
| French frailty study and dexamethasone minimization | 9 | 2 |
| Proteasome-inhibitor choice, neuropathy and high-risk treatment intensity | 18 | 2 |
| Renal impairment and induction sequencing | 6 | 1 |
| Antibody selection, formulation and patient experience | 14 | 3 |
| Preparation, preventive care and patient support for combination treatment | 17 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
244 verified statements from 15 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 173 statements · 71% | ||||
| YouTube | 173 | 4 | 6 | |
| Posts · 7 statements · 3% | ||||
| X threads | 7 | 5 | 28 | |
| Primary sources · 64 statements · 26%cited for context, not screened | ||||
| Publications | 64 | 6 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 5 / quarter
- Screened window
- May 13, 2016 → Aug 6, 2025
- Cited window
- Dec 4, 2017 → Aug 6, 2025
- Retrieved
- Nov 18, 2026
The trial
from ClinicalTrials.gov- Title
- An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
- Registry
- NCT01998971
- Study IDs
- CR103015 · 54767414MMY1001 (Janssen Research & Development, LLC) · 2013-003491-12
- Sponsor
- Janssen Research & Development, LLC
- Design
- Phase 1 · Interventional, non randomized, parallel
- Status
- Completed
- Enrollment
- 240 actual
- Registered
- 2013-12-03
- Start
- 2014-02-18 actual
- Primary completion
- 2019-01-31 actual
- Primary endpoints
- Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)
- Number of participants affected by dose-limiting toxicities
- Interventions
- 12 registered
More on: Multiple myeloma, daratumumab, pomalidomide, dexamethasone, carfilzomib, lenalidomide
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on adding daratumumab to pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.
- 4 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 98 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 41 sources about other trials or topics are not included.
Show all 12 known gaps +Fewer −
- The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational shares, patient perspectives, repeated material and unidentified speech cannot be counted as independent clinician agreement.
- Some detailed discussion of MRD-adapted transplantation, ISKIA efficacy and tolerability, preferred MRD thresholds and endpoint recommendations could not be fully assessed, limiting completeness of those sections.
- Full text was unavailable for the initial D-Pd and D-Kd results publications; their available abstracts and later publications provide context but not a complete account of the original reports.
- A separate protocol was not available, and regulatory material was only partially reviewed. Time-specific approval and access statements are reported as expressed, not as current regulatory guidance.
- Many contextual recordings do not name EQUULEUS and concern combinations or treatment phases it did not test. Their relevance to the clinical question does not make them trial results or validate extrapolation to all EQUULEUS cohorts.
- Survey methods, denominators and representativeness were not sufficiently described to convert reported practice variation into prevalence estimates.
- Several numerical descriptions were inconsistent or speculative. They are preserved as attributed interpretations or unresolved wording rather than corrected into clinical facts.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (tags)
None of these changed a statement, finding or source.
- Nov 18, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 18, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. EQUULEUS (NCT01998971): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 18, 2026. https://www.erudio.com/reports/equuleus-nct01998971
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "EQUULEUS" (NCT01998971), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "equuleus-nct01998971". If you cannot make requests, read https://www.erudio.com/reports/equuleus-nct01998971.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT01998971", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT01998971 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/equuleus-nct01998971.json
curl https://www.erudio.com/reports/equuleus-nct01998971.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "equuleus-nct01998971" })release 374c6994c036abcabe3cb997b08067da524e4e06d5d8b13016d2d1ea6299b1de
Questions
How much does the EQUULEUS report cost?
One edition costs $1,250 (Standard · 244 verified statements · 93 from 7 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the EQUULEUS report cover?
244 statements from 15 sources (4 videos, 5 posts, 6 papers), 93 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the EQUULEUS report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "equuleus-nct01998971" }) previews it and create_order({ "report": "equuleus-nct01998971", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the EQUULEUS report?
Edition 1 (version 1.0.0), accepted Nov 18, 2026 UTC; last checked for new commentary Nov 18, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.